MacroGenics MQGAU Bond

MGNX Stock  USD 3.34  0.14  4.02%   
MacroGenics holds a debt-to-equity ratio of 0.162. Net Debt is likely to drop to about (70.3 M) in 2024. Short Term Debt is likely to drop to about 3.6 M in 2024 With a high degree of financial leverage come high-interest payments, which usually reduce MacroGenics' Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

MacroGenics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. MacroGenics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps MacroGenics Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect MacroGenics' stakeholders.
For most companies, including MacroGenics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for MacroGenics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, MacroGenics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
1.7825
Book Value
1.913
Operating Margin
0.4895
Profit Margin
(0.69)
Return On Assets
(0.22)
Non Current Liabilities Total is likely to rise to about 94.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 47.8 M in 2024.
  
Check out the analysis of MacroGenics Fundamentals Over Time.
For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.
View Bond Profile
Given the importance of MacroGenics' capital structure, the first step in the capital decision process is for the management of MacroGenics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of MacroGenics to issue bonds at a reasonable cost.
Popular NameMacroGenics MQGAU 134 12 JAN 27
SpecializationPharmaceuticals, Biotechnology & Life Sciences
Equity ISIN CodeUS5560991094
Bond Issue ISIN CodeUS55608KAR68
S&P Rating
Others
Maturity DateOthers
Issuance DateOthers
View All MacroGenics Outstanding Bonds

MacroGenics Outstanding Bond Obligations

Dana 575 percentUS235822AB96Details
Volcan Compania MineraUSP98047AC08Details
MQGAU 3052 03 MAR 36US556079AD36Details
MQGAU 3624 03 JUN 30US556079AC52Details
MQGAU 6798 18 JAN 33US556079AF83Details
Boeing Co 2196US097023DG73Details
MQGAU 23 22 JAN 25US55608PBE34Details
MQGAU 5757067 21 MAR 25US55608PBK93Details
MQGAU 3231 21 MAR 25US55608PBJ21Details
MQGAU 4654 27 MAR 29US55608KAN54Details
MQGAU 5033 15 JAN 30US55608KAP03Details
MQGAU 3763 28 NOV 28US55608KAK16Details
MQGAU 134 12 JAN 27US55608KAR68Details
MQGAU 4098 21 JUN 28US55608KBC80Details
MQGAU 2871 14 JAN 33US55608KAZ84Details
MQGAU 5108 09 AUG 26US55608KBF12Details
MQGAU 5491 09 NOV 33US55608KBG94Details
MPLX LP 4875US55336VAG59Details
MPLX LP 4125US55336VAK61Details
MPLX LP 52US55336VAL45Details
MQGAU 1629 23 SEP 27US55607PAF27Details
MQGAU 2691 23 JUN 32US55607PAG00Details
MQGAU 5376057 23 SEP 27US55607PAE51Details
MQGAU 5033 15 JAN 30US55608JAP30Details
MQGAU 134 12 JAN 27US55608JAR95Details
MQGAU 1935 14 APR 28US55608JAX63Details
MQGAU 2871 14 JAN 33US55608JAZ12Details
MQGAU 3763 28 NOV 28US55608JAK43Details
MQGAU 4654 27 MAR 29US55608JAN81Details
MQGAU 5108 09 AUG 26US55608JBF49Details
MQGAU 5491 09 NOV 33US55608JBG22Details
MQGAU 4098 21 JUN 28US55608JBC18Details
MQGAU 4442 21 JUN 33US55608JBE73Details
MQGAU 3231 21 MAR 25US55608RBJ86Details
MQGAU 39 15 JAN 26US55608RAW07Details
Morgan Stanley 3591US61744YAK47Details
Morgan Stanley 3971US61744YAL20Details
MGM Resorts InternationalUS552953CD18Details
Valero Energy PartnersUS91914JAA07Details
MQGAU 4875 10 JUN 25US55608YAB11Details

Understaning MacroGenics Use of Financial Leverage

Understanding the structure of MacroGenics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to MacroGenics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last ReportedProjected for Next Year
Net Debt-67 M-70.3 M
Short Term Debt3.8 M3.6 M
Short and Long Term Debt Total34 M18.7 M
Long Term Debt Total268.2 K254.8 K
Net Debt To EBITDA(33.21)(31.55)
Debt To Equity 0.02  0.02 
Interest Debt Per Share 0.08  0.06 
Debt To Assets 0.01  0.01 
Long Term Debt To Capitalization 0.01  0.01 
Total Debt To Capitalization 0.02  0.01 
Debt Equity Ratio 0.02  0.02 
Debt Ratio 0.01  0.01 
Cash Flow To Debt Ratio(20.72)(21.75)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.